

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

January 30, 2024

Terrance Coyne Chief Financial Officer Royalty Pharma plc 110 East 59th Street New York, NY 10022

> Re: Royalty Pharma plc Form 10-K for the period ended December 31, 2022 Filed February 15, 2023 File No. 001-39329

Dear Terrance Coyne:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences